ArticleMedicine2026
Study on the expression characteristics of CA125 in patients with SLE and its correlation with clinical indicators.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the role of carbohydrate antigen 125 (CA125) in the pathogenesis of systemic lupus erythematosus (SLE) and analyzes factors associated with its elevation. A total of 220 patients diagnosed with SLE at the Department of Rheumatology and Immunology of our institution between January 2021 and January 2025 were enrolled. Among them, 63 patients with positive CA125 were assigned to the observation group, and 157 with negative CA125 served as the control group. Demographic data, clinical manifestations, and laboratory parameters were collected. Univariate and binary logistic regression analyses were performed to identify factors associated with CA125 positivity and to evaluate correlations between CA125 levels and clinical indicators. Logistic regression revealed that hypoproteinemia (odds ratio [OR] = 3.796, P = .034), serous cavity effusion (OR = 3.169, P = .045), albumin (ALB; OR = 1.121, P = .01), complement 3 (C3; OR = 1.568, P = .048), 25-hydroxyvitamin D3 (25(OH)D3; OR = 1.267, P = .013), SLE Disease Activity Index (SLEDAI; OR = 0.764, P = .019), and interleukin-6 (IL-6; OR = 0.960, P = .009) were associated with elevated CA125. Regression analysis showed that CA125 was negatively correlated with 25(OH)D3 and ALB, and positively correlated with SLEDAI and IL-6. Hypoproteinemia and serous cavity effusion were independent predictors of elevated CA125 in SLE patients. These findings suggest that CA125 may serve as a potential serological marker reflecting disease activity and systemic inflammation in SLE, offering supportive value for clinical assessment and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.